Tetra Bio-Pharma's Rx Princeps Becomes Available Through Aphria

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced the availability of the Rx Princeps products through licensed producer Aphria (TSX:APH; OTCQB:APHQF).
As quoted in the press release:

Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now entering this lucrative market and plans on progressively grabbing a significant share of it over the next two years. Mr Fortier, CEO of Tetra, stated last week “We are expecting to generate around $1.5 million in sales, in fiscal 2018 in our initial launch. Through our promotion and education efforts in Quebec, New Brunswick and part of Ontario, we estimate that over eight thousand patients will start using Rx Princeps™ under prescription from their doctors over in the next twelve months.”
Rx Princeps™ is a new option for doctors who want to prescribe medical cannabis. Prescribing Rx Princeps™ with the Rx Princeps™ inhalation device enables their patients to optimize the benefits of medical cannabis through the intake of a fixed dose of product, thereby ensuring consistency of treatment with a standardized high-quality product.

Click here to read the full press release.

Source: www.marketwired.com